EP0385584B1 - Verfahren zur Herstellung von 4-(Cycloamido)-2H-1-benzopyranen mit 4-Amino-3-hydroxy-2H-1-benzopyranen - Google Patents

Verfahren zur Herstellung von 4-(Cycloamido)-2H-1-benzopyranen mit 4-Amino-3-hydroxy-2H-1-benzopyranen Download PDF

Info

Publication number
EP0385584B1
EP0385584B1 EP90301063A EP90301063A EP0385584B1 EP 0385584 B1 EP0385584 B1 EP 0385584B1 EP 90301063 A EP90301063 A EP 90301063A EP 90301063 A EP90301063 A EP 90301063A EP 0385584 B1 EP0385584 B1 EP 0385584B1
Authority
EP
European Patent Office
Prior art keywords
alkyl
compound
carbon atoms
formula
isomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP90301063A
Other languages
English (en)
French (fr)
Other versions
EP0385584A1 (de
Inventor
Erol Ali Beecham Pharmaceuticals Faruk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beecham Group PLC
Original Assignee
Beecham Group PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beecham Group PLC filed Critical Beecham Group PLC
Publication of EP0385584A1 publication Critical patent/EP0385584A1/de
Application granted granted Critical
Publication of EP0385584B1 publication Critical patent/EP0385584B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/68—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with nitrogen atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6

Definitions

  • the present invention relates to a process for the preparation of one isomeric form of chemical compounds having pharmacological activity.
  • EP-A-0076075 (Beecham Group p.l.c.) discloses a class of 3,4-dihydrobenzopyranols, and corresponding esters and ethers, with an oxo-pyrrolidinyl or oxo-piperidinyl substituent at the 4-position. These compounds are disclosed as having a blood pressure lowering activity.
  • EP-A-0120428 (Beecham Group p.l.c.) discloses that the (3S,4R)-isomer of the above compounds has greater blood pressure lowering activity than the (3R,4S)-isomer.
  • EP-A-0120428 are of general formula (A): wherein one of R1 and R2 is hydrogen and the other is selected from the class of alkylcarbonyl, alkoxycarbonyl, alkylcarbonyloxy, alkylhydroxymethyl, nitro, cyano, chloro, trifluoromethyl, alkylsulphinyl, alkylsulphonyl, alkoxysulphinyl, alkoxysulphonyl, alkylcarbonylamino, alkoxycarbonylamino or aminosulphinyl, aminosulphonyl or aminocarbonyl, the amino moiety being optionally substituted by one or two alkyl groups, or alkylsulphinylamino, alkylsulphonyl-amino, alkoxysulphinylamino or alkoxysulphonylamino or ethylenyl terminally substituted by alkylcarbonyl, nitro or cyano, or -C(alkyl
  • the (3S,4R)-isomer of a compound of formula (A) is of formula (A'): wherein the variables are as defined in formula (I).
  • the (3S,4R)-isomers of compounds of formula (A) have the same configuration as that enantiomer of a compound of formula (B) which has a negative optical rotation: the OH and pyrrolidon-1-yl groups in formula (B) being mutually trans.
  • the compound of formula (B) is trans-6-cyano-3,4-dihydro-2,2-dimethyl-4-(2-oxo-1-pyrrolidinyl)benzo[b]pyran-3-ol, also known as cromakalim, the (-)-isomer thereof, being known as lemakalim.
  • EP-A-0120428 is a resolution process for separating the (3S,4R)-isomer of compounds of formula (A) from a mixture with the (3R,4S)-isomer by fractional crystallisation, exemplified by a carbamate derivative obtained by reaction with (-)- ⁇ -methyl benzyl isocyanate.
  • the compound of formula (A) is obtained by cyclising a compound of formula (C) or formula (D): wherein R1', R2' are R1 or R2 or a group or atom convertible thereto, R1 to R5 and n are as hereinbefore defined and L1 and L3 are leaving groups, and wherein the substituted amino group is trans to the OR5 group; where necessary converting R1' and/or R2' to R1 and/or R2; and optionally converting R5 to another R5 as hereinbefore defined.
  • the leaving group L1 is a group that is displaceable by a secondary amino nucleophile.
  • the leaving group L3 is a group that is displaceable by a secondary amino nucleophile adjacent to a carbonyl function.
  • compounds of formula (A) are preferably formed by a procedure in which the pyrrolidonyl or piperidonyl ring is formed by cyclisation as a final step, it is advantageous to perform the resolution to isolate or concentrate the (3S,4R)-configuration before the cyclisation takes place.
  • the present invention provides a process for the preparation of a pure (3S, 4R)-isomer of a compound of formula (A): wherein one of R1 and R2 is hydrogen and the other is selected from the group consisting of alkylcarbonyl, alkoxycarbonyl, alkylcarbonyloxy, alkylhydroxymethyl, nitro, cyano, chloro, trifluoromethyl, alkylsulphinyl, alkylsulphonyl, alkoxysulphinyl, alkoxysulphonyl, alkylcarbonylamino, alkoxycarbonylamino, aminosulphinyl, aminosulphonyl, and aminocarbonyl, the amino moiety thereof being optionally substituted by one or two alkyl groups, alkylsulphinylamino, alkylsulphonylamino, alkoxysulphinylamino, alkylsulphonylamino, ethylenyl terminally substituted
  • the cyclisation is performed on a compound of formula (D) as defined above of the appropriate configuration.
  • the leaving group L3 is preferably chloro.
  • the cyclisation can be carried out in a solvent in the presence of a base, for example dimethylformamide and sodium hydride, or ethanol or toluene and sodium methoxide.
  • a base for example dimethylformamide and sodium hydride, or ethanol or toluene and sodium methoxide.
  • Alkali metal alcoholates such as potassium tert butoxide or sodium iso propoxide are also suitable bases.
  • the base is added to the compound to be cyclised while the latter is still in the solvent used during introduction of the cyclisable ligand, as described below. (i.e. the compound of formula (C) or (D) is used in situ ).
  • Reaction of the corresponding aminoalcohol of formula (E) reaction preferably takes place in a solvent to which the base required for promotion of cyclisation can be added directly.
  • Suitable solvents include for example, N-methylpyrrolidone, dimethylformamide, dimethylpropylene urea, dimethylimidazolidinone, tetrahydrofuran or other ethers, and toluene.
  • a racemic mixture of the amino alcohol of formula (E) is preferably obtained by reaction of the corresponding epoxy compound of formula (H): with ammonium hydroxide, in a lower alcohol, preferably a C1-3 alkanol, such as propan-2-ol.
  • R1' or R2' is a group or atom convertible to the defined class of substituents for R1 or R2.
  • Such conversions are generally well-known in the art.
  • a hydrogen atom may be replaced by a nitro group by nitrating in a known manner a compound, wherein one of R1' and R2' is hydrogen.
  • R1' or R2' is a group or atom convertible to hydrogen
  • such conversions are also generally well-known in the art.
  • the acetamido group may be replaced by a hydrogen atom by hydrolysing a compound wherein one of R1' and R2' is acetamido, converting the resulting amine into a diazonium salt, and finally decomposing it under reductive conditions.
  • one of R1 and R2 is hydrogen.
  • the other is preferably selected from the class of alkylcarbonyl, alkoxycarbonyl, nitro or cyano, in particular nitro or cyano.
  • alkyl groups or alkyl moieties of alkyl-containing groups are preferably methyl or ethyl.
  • R2 is hydrogen and R1 is selected from the class of substituents as defined hereinbefore. It is particularly preferred that R2 is hydrogen and R1 is nitro or cyano. It is also preferred that R2 is hydrogen and R1 is acetyl.
  • R1 and/or R2 may also be selected from the values disclosed for the corresponding variables in EP-A-314446 (American Home Products Corporation), EP-A-296975 and 312432 (Sanofi), EP-A-298452 (F. Hoffmann-La Roche and Co.), EP-A-273262, EP-A-308972 and 340718 (Merck Patent GmbH), EP-A-277611,EP-A-277612 and 337179 (Hoechst Aktiengesellschaft), EP-A-339562 (Yoshitomi Pharmaceutical Industries Ltd.), GB 2204868A (Sandoz Limited) and WO 89/07103 (Nissan Chemical Industries Ltd.).
  • R3 and R4 are preferably both alkyl having from 1 to 4 carbon atoms. In particular they are each methyl or ethyl, preferably each methyl.
  • R5 is alkyl
  • preferred examples thereof include methyl, ethyl and n-propyl, of which methyl is most preferred.
  • R5 is acyl
  • a preferred class is unsubstituted carboxylic acyl, such as aliphatic acyl or benzoyl.
  • R5 however is preferably hydrogen.
  • the (3S,4R)-isomer of a compound of formula (A) or an intermediate of formula (C), (D) or (E), is in a form containing from 0 to 40%, 0 to 30%, 0 to 20% or 0 to 10% of the corresponding (3R,4S)-isomer. More preferably, the (3S,4R)-isomer is in a form containing 0 to 5% of the corresponding (3R,4S)-isomer. Most preferably, the (3S,4R)-isomer is in a form containing 0% or no detectable amount of the corresponding (3R,4S)-isomer. All percentages hereinbefore are percentages of the mixture by weight.
  • the presence of (3R,4S)-isomer may, for example, be routinely detected by the comparison of the optical rotation of a sample of the isomeric mixture with that of a pure sample of the (3S,4R)-isomer, or by the 1H nmr spectrum of a sample of the isomeric mixture in the presence of a chiral shift reagent or chiral solvating agent.
  • resolution is used herein in the conventional practical sense used in the art to include partial resolution, that is, the separation of a mixture of enantiomers of a compound (in any ratio) into two fractions, one of which is enriched in one enantiomer relative to the initial mixture.
  • Resolution may be effected conventionally by derivatising the mixture with a chiral derivatising agent, to form a mixture of diastereomers.
  • the components of the mixture may then be separated conventionally, for example by fractional crystallisation. Separation may be complete, or partial.
  • each isomer of a compound of formula (A), (C), (D) or (E), at the 3- and 4-centres may conveniently be determined by routine and conventional X-ray crystallographic analysis of an isolated diastereomeric derivative of that isomer, the configuration at the 3- and 4- centres of the isomer and its derivative being the same.
  • an isomer of a compound of formula (A) wherein R5 is H may be reacted with a chiral esterifying agent with retention of 3- and 4- centre configuration to form a diastereomeric ester derivative of the isomer. This may be isolated as a crystalline solid and the crystals used for the foregoing X-ray analysis.
  • An isomer of a compound of formula (A) wherein R5 is an alkyl or acyl group as hereinbefore defined may be converted conventionally to the corresponding isomer of a compound of formula (A) wherein R5 is H, with retention of 3- and 4- centre configuration. This may then be derivatised and its absolute configuration determined as described hereinbefore.
  • optical rotation of any similarly resolved and isolated enantiomer of any of the other compounds mentioned above may be routinely ascertained by conventional methods.
  • the (3S,4R)-isomer of a compound of formula (I) has a better blood pressure lowering activity that the corresponding (3R,4S)-isomer. This isomer is therefore useful in the treatment of hypertension, optionally in admixture with the corresponding (3R,4S)-isomer as hereinbefore defined.
  • Example 1 Alternative procedures for the cyclisation areillustrated in Example 1; one involving different solvents for introduction of the cyclisable ligand and adding the base to promote cyclisation, the other using a common solvent for both procedures.
  • Triethylamine (7.95g) was added to a stirred solution of (+)- trans -4-amino-6-cyano-3,4-dihydro-2,2-dimethyl- 2H-1-benzopyran-3-ol (16.35g) in dry tetrahydrofuran (40ml) kept under a nitrogen atmosphere. The mixture was cooled to 15°C and a solution of 4-chlorobutyryl chloride (11.45g) in dry tetrahydrofuran (9ml) added over 45 min while maintaining the reaction temperature at 15-25°C with external cooling.
  • Triethylamine (10.85g) was added to a stirred solution of (+)- trans -4-amino-6-cyano-3,4-dihydro-2,2-dimethyl- 2H-1-benzopyran-3-ol (21.8g) in N-methylpyrrolidone (100ml) kept under a nitrogen atmosphere. The mixture was cooled to 5°C and 4-chlorobutyryl chloride (15.15g) added over 1 hour maintaining the reaction temperature below 20°C with external cooling.
  • Triethylamine (42.7g) was added to this stirred solution.
  • the mixture was cooled to 5°C and 4-chlorobutyrylchloride (59.6g) added over 30 minutes maintaining the reaction temperature below 30°C with external cooling.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Claims (4)

  1. Verfahren zur Herstellung eines reinen (3S,4R)-Isomers einer Verbindung der Formel (A):
    Figure imgb0013
     in der
    einer der Reste R₁ und R₂ ein Wasserstoffatom ist, und der andere ausgewählt ist aus einem Alkylcarbonyl-, Alkoxycarbonyl-, Alkylcarbonyloxy-, Alkylhydroxymethylrest, einer Nitro-, Cyanogruppe, einem Chloratom, einer Trifluormethylgruppe, einem Alkylsulfinyl-, Alkylsulfonyl-, Alkoxysulfinyl-, Alkoxysulfonyl-, Alkylsarbonylamino-, Alkoxycarbonylaminorest, einer Aminosulfinyl-, Aminosulfonyl- und Aminocarbonylgruppe, wobei deren Aminoeinheit gegebenenfalls mit einem oder zwei Alkylresten substituiert ist, einem Alkylsulfinylamino-, Alkylsulfonylamino-, Alkoxysulfinylamino-, Alkylsulfonylaminorest und einer Ethylenylgruppe, die endständig mit einem Alkylcarbonylrest, einer Nitro-, Cyanogruppe, einem Rest der Formel -C(Alkyl)NOH oder -C(Alkyl)NNH₂ substituiert ist, wobei die Alkylreste oder Alkyleinheiten der Alkylreste enthaltenden Reste 1 bis 6 Kohlenstoffatome aufweisen;
    einer der Reste R₃ und R₄ ein Wasserstoffatom oder ein Alkylrest mit 1 bis 4 Kohlenstoffatomen ist, und der andere ein Alkylrest mit 1 bis 4 Kohlenstoffatomen ist, oder R₃ und R₄ zusammen einen Polymethylenrest mit 2 bis 5 Kohlenstoffatomen bilden;
    R₅ ein Wasserstoffatom, ein Alkylrest mit 1 bis 3 Kohlenstoffatomen oder ein Carboxyacylrest mit 1 bis 8 Kohlenstoffatomen ist; und
    n 1 oder 2 ist;
    das das Cyclisieren einer Dihydrobenzopyranolvorstufenverbindung der Formel (C) oder (D) umfaßt:
    Figure imgb0014
     in der R₁' und R₂' R₁ oder R₂ sind, R₁ bis R₅ und n wie vorstehend definiert sind, und L₁ und L₃ Abgangsgruppen sind, und in der sich die substituierte Aminogruppe in trans-Stellung zu dem Rest der Formel OR₅ befindet; wenn nötig, das Umwandeln von R₁' und/oder R₂' in R₁ und/oder R₂; und gegebenenfalls das Umwandeln des Restes R₅ in einen anderen Rest R₅ umfaßt, wobei vor der Cyclisierung die Vorstufenverbindung (C) oder (D) in die (3S,4R)-Konfiguration oder in ein Gemisch aufgetrennt wurde, in dem die (3S,4R)-Konfiguration hinsichtlich der (3S,4R)-Konfiguration überwiegt, indem (i) eine Verbindung der Formel (E):
    Figure imgb0015
     in der sich die NH₂- und OH-Einheiten in trans-Stellung befinden, und R₃, R₄, R₁' und R₂' wie vorstehend definiert sind, unter Verwendung von (+)endo-3-Bromcampher-9-sulfonsäure oder deren Ammoniumsalz als Trennmittel durch fraktionierte Kristallisation aufgetrennt wird, wobei das (3S,4R)-Isomer isoliert wird; und indem (ii) das (3S,4R)-Isomer der Verbindung der Formel (E) mit einer Verbindung der Formel (F) oder (G)



            L₂(CH)₂)n+2COL₁   (F)





            L₃(CH)₂)n+2COL₄   (G)



    in der L₂ eine Abgangsgruppe ist, und L₄ eine Abgangsgruppe ist, umgesetzt wird, wobei die Vorstufenverbindung (C) oder (D) gebildet wird.
  2. Verfahren gemäß Anspruch 1, wobei die Cyclisierung an einer Verbindung der Formel (D), in der L₃ ein Chloratom ist, durchgeführt wird.
  3. Verfahren gemäß Anspruch 1, wobei die zu cyclisierende Verbindung in situ verwendet wird.
  4. Verfahren gemäß Anspruch 1 zur Herstellung von (-)trans-6-Cyano-3,4-dihydro-2,2-dimethyl-4-(2-oxo-1-pyrrolidinyl)benzo[b]pyran-3-ol.
EP90301063A 1989-02-01 1990-02-01 Verfahren zur Herstellung von 4-(Cycloamido)-2H-1-benzopyranen mit 4-Amino-3-hydroxy-2H-1-benzopyranen Expired - Lifetime EP0385584B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898902118A GB8902118D0 (en) 1989-02-01 1989-02-01 Chemical process
GB8902118 1989-02-01

Publications (2)

Publication Number Publication Date
EP0385584A1 EP0385584A1 (de) 1990-09-05
EP0385584B1 true EP0385584B1 (de) 1995-05-24

Family

ID=10650905

Family Applications (1)

Application Number Title Priority Date Filing Date
EP90301063A Expired - Lifetime EP0385584B1 (de) 1989-02-01 1990-02-01 Verfahren zur Herstellung von 4-(Cycloamido)-2H-1-benzopyranen mit 4-Amino-3-hydroxy-2H-1-benzopyranen

Country Status (23)

Country Link
US (1) US5126460A (de)
EP (1) EP0385584B1 (de)
JP (1) JP2859348B2 (de)
KR (1) KR0179364B1 (de)
AT (1) ATE123029T1 (de)
AU (1) AU626376B2 (de)
CA (1) CA2008940C (de)
DE (1) DE69019554T2 (de)
DK (1) DK0385584T3 (de)
ES (1) ES2074532T3 (de)
FI (1) FI900499A0 (de)
GB (1) GB8902118D0 (de)
GR (1) GR3017077T3 (de)
HK (1) HK1006308A1 (de)
HU (1) HUT58074A (de)
IE (1) IE66738B1 (de)
IL (1) IL93229A0 (de)
MA (1) MA21741A1 (de)
NO (1) NO900420L (de)
NZ (1) NZ232289A (de)
PT (1) PT92999B (de)
TW (1) TW206213B (de)
ZA (1) ZA90660B (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102863374A (zh) * 2005-08-31 2013-01-09 ARYx医疗有限公司 用于治疗胃肠***和中枢神经***疾病的立体异构化合物的合成方法及中间体

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5095016A (en) * 1989-08-11 1992-03-10 Kaken Pharmaceutical Co., Ltd. Benzopyran compounds, processes for their production and pharmaceutical compositions
US5276168A (en) * 1990-06-18 1994-01-04 E. R. Squibb & Sons, Inc. Benzopyran derivatives and heterocyclic analogs thereof as antiischemic agents
US5869478A (en) * 1995-06-07 1999-02-09 Bristol-Myers Squibb Company Sulfonamido substituted benzopyran derivatives
US5612370A (en) * 1995-06-07 1997-03-18 Bristol-Myers Squibb Company Phenylglycine and phenylalaninen amido benzopyran derivatives
US5612323A (en) * 1995-06-07 1997-03-18 Bristol-Myers Squibb Company Phosphinic ester substituted benzopyran derivatives
US5629429A (en) * 1995-06-07 1997-05-13 Bristol-Myers Squibb Company Process for preparing 4-arylamino-benzopyran and related compounds
AU2005316739A1 (en) * 2004-12-13 2006-06-22 Galileo Pharmaceuticals, Inc. Spiro derivatives as lipoxygenase inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2523281A1 (de) * 1974-05-31 1975-12-11 Beecham Group Ltd Derivate des trans-3-hydroxy-4-amino-chromans, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
EP0260555A1 (de) * 1986-09-10 1988-03-23 The Du Pont Merck Pharmaceutical Company Kondensierte Benzo-cycloalkane und Oxa- und Thia-cycloalkane trans-1,2-diamine-Derivate

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1548222A (en) * 1976-12-17 1979-07-04 Beecham Group Ltd Trans-4-heterocyclyl-3,4-dihydro-2h-benzo pyarn-3-ol derivatives
GB2107706A (en) * 1981-09-25 1983-05-05 Beecham Group Plc Benzopyrans
DE3368629D1 (en) * 1982-04-28 1987-02-05 Beecham Group Plc Novel chromenes and chromans
GB8308062D0 (en) * 1983-03-24 1983-05-05 Beecham Group Plc Active compounds
GB8308063D0 (en) * 1983-03-24 1983-05-05 Beecham Group Plc Active compounds
GB8313679D0 (en) * 1983-05-18 1983-06-22 Beecham Group Plc Active compounds
DE3475786D1 (de) * 1983-09-01 1989-02-02 Beecham Group Plc Chromanol derivatives
CH674984A5 (de) * 1987-05-16 1990-08-15 Sandoz Ag
FI90343C (fi) * 1987-06-23 1994-01-25 Merck Patent Gmbh Menetelmä korkeaa verenpainetta alentavien ja rytmihäiriöitä vastustavien trans-2,2-dimetyylikroman-3-olijohdannaisten valmistamiseksi
DE3823533A1 (de) * 1988-07-12 1990-02-08 Beiersdorf Ag Substituierte 4-heterocyclyl-2h-benzo(b)pyrane, verfahren und 4-hydroxy-3-brom-, 3,4-oxiranyl-3,4-dehydro-2h-benzo(b)pyrane als zwischenprodukte zu ihrer herstellung, sowie sie enthaltende pharmazeutsche praeparate
GB8918298D0 (en) * 1989-08-10 1989-09-20 Beecham Group Plc Novel compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2523281A1 (de) * 1974-05-31 1975-12-11 Beecham Group Ltd Derivate des trans-3-hydroxy-4-amino-chromans, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
EP0260555A1 (de) * 1986-09-10 1988-03-23 The Du Pont Merck Pharmaceutical Company Kondensierte Benzo-cycloalkane und Oxa- und Thia-cycloalkane trans-1,2-diamine-Derivate

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 109, no. 25, December 19, 1988, Columbus, Ohio, USA BEECHAM GROUP PLC " Benzopyran derivatives, their preparation, and pharmaceutical compositions containing them" & Jpn. Kokai Tokkyo Koho JP 62,273,972 (87,273,972) *
CHEMICAL ABSTRACTS, vol. 99, no. 19, November 7, 1983, Columbus , Ohio, USA EVANS, JOHN M. "Synthesis and antihypertensives activity of substituded trans-4-amino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ols" *
CHEMICAL ABSTTTTRACTS, vol. 101, no.11, September 10, 1984, Columbus, Ohio, USA EVANS, JOHN M. "Synthesis and antihypertensive activity of 6,7-disubstituted trans-4-amino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ols" *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102863374A (zh) * 2005-08-31 2013-01-09 ARYx医疗有限公司 用于治疗胃肠***和中枢神经***疾病的立体异构化合物的合成方法及中间体

Also Published As

Publication number Publication date
ES2074532T3 (es) 1995-09-16
DE69019554D1 (de) 1995-06-29
HUT58074A (en) 1992-01-28
HK1006308A1 (en) 1999-02-19
PT92999B (pt) 1995-12-29
HU900588D0 (en) 1990-04-28
GR3017077T3 (en) 1995-11-30
KR0179364B1 (ko) 1999-03-20
AU626376B2 (en) 1992-07-30
MA21741A1 (fr) 1990-10-01
TW206213B (de) 1993-05-21
FI900499A0 (fi) 1990-01-31
NO900420L (no) 1990-08-02
JPH02240079A (ja) 1990-09-25
AU4892190A (en) 1990-08-09
KR900012931A (ko) 1990-09-03
CA2008940C (en) 2000-12-05
EP0385584A1 (de) 1990-09-05
IE66738B1 (en) 1996-02-07
DE69019554T2 (de) 1995-09-28
IL93229A0 (en) 1990-11-05
IE900342L (en) 1990-08-01
PT92999A (pt) 1990-08-31
CA2008940A1 (en) 1990-08-01
GB8902118D0 (en) 1989-03-22
NZ232289A (en) 1992-09-25
ATE123029T1 (de) 1995-06-15
US5126460A (en) 1992-06-30
JP2859348B2 (ja) 1999-02-17
ZA90660B (en) 1992-05-27
DK0385584T3 (da) 1995-07-17
NO900420D0 (no) 1990-01-30

Similar Documents

Publication Publication Date Title
JP2504708B2 (ja) 化学中間体
AU678605B2 (en) Processes for the preparation of pesticides and intermediates
EP1919897A1 (de) Verfahren zur herstellung von esomeprazol und salzen davon
CA1284150C (en) (3s,4r)-trans-4-pyrrolidon/piperidon-1-yl-3,4-dihydro-2h- benzo ¬b|pyran-3-olderivatives
Lewis et al. A simple and efficient procedure for the preparation of chiral 2-oxazolidinones from α-amino acids
EP0385584B1 (de) Verfahren zur Herstellung von 4-(Cycloamido)-2H-1-benzopyranen mit 4-Amino-3-hydroxy-2H-1-benzopyranen
EP1551839B1 (de) Verfahren zur herstellung von 9-¬4-acetoxy-3-(acetoxymethyl)but-1-yl -2-aminopurin
US5239090A (en) Certain optically active 3,4-dihydrobenzopyran-4-ols which are intermediates
SK179097A3 (en) Process for the production of enantiomerically-pure azetidine-2-carboxylic acid
US5675005A (en) Process for preparing xanthine derivatives, in particular 1,3-dipropyl-8-(3-oxocyclopentyl)-xanthine
EP1817273B1 (de) Verfahren zur herstellung von diastereoisomeren von 4-hydroxyisoleucin
CA2276320C (en) L-tartrate of trans-(-)-4-(4-fluorophenyl)-3-hydroxymethylpiperidine compound and process for preparing the same
CN101952271A (zh) 用于制备2h-色烯-3-氨基甲酸酯衍生物的方法
HU191682B (en) Process for preparing 1-benzyl-azetidin-3-ol derivatives
US4485248A (en) Process for producing 2,4-diamino-(3,5-dimethoxy-4-methoxyethoxy-benzyl)-pyrimidine
HU181503B (en) Process for producing 3,3-ethylenedioxy-4,5-seco-19-nor-androst-9-ene-5,17-dione
US5599949A (en) Bisphenol derivative and its manufacturing method
CN115141251A (zh) 一种雷替曲塞杂质及其制备方法、应用
EP0441116B1 (de) Verfahren und Zwischenprodukte zur Herstellung von optisch aktiven Chromanderivaten
JPH07258264A (ja) 光学活性な３，４−エポキシ−３，４−ジヒドロ−２ｈ−１−ベンゾピラン化合物の対応する鏡像異性体への反転方法
KR20200046290A (ko) 아픽사반의 제조방법
KR20060125218A (ko) 광학활성 벤족사진 유도체의 제조방법

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17P Request for examination filed

Effective date: 19901005

17Q First examination report despatched

Effective date: 19921202

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BEECHAM GROUP PLC

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

REF Corresponds to:

Ref document number: 123029

Country of ref document: AT

Date of ref document: 19950615

Kind code of ref document: T

REF Corresponds to:

Ref document number: 69019554

Country of ref document: DE

Date of ref document: 19950629

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

ITF It: translation for a ep patent filed

Owner name: SOCIETA' ITALIANA BREVETTI S.P.A.

ET Fr: translation filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2074532

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: GR

Ref legal event code: FG4A

Free format text: 3017077

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19960229

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 19990107

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19990204

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 19991203

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20000127

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000202

EUG Se: european patent has lapsed

Ref document number: 90301063.5

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010228

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20050110

Year of fee payment: 16

Ref country code: GB

Payment date: 20050110

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20050202

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20050217

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20050228

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20050304

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20050317

Year of fee payment: 16

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060202

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060228

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060228

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060228

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20060228

Year of fee payment: 17

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060901

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060901

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20060201

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20060901

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20061031

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20060202

BERE Be: lapsed

Owner name: *BEECHAM GROUP P.L.C.

Effective date: 20060228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070201